Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Option Exercise and Share Sales

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 1, 2024, Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options to acquire 1,667 shares of common stock at a price of $21.41 per share.
• On the same day, Eydelman sold 1,482 shares at a weighted-average price of $78.7998, with prices ranging from $78.23 to $79.22.
• Additionally, Eydelman sold 185 shares at a weighted-average price of $79.2859, with prices ranging from $79.23 to $79.34.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 29, 2023.
• Following these transactions, Eydelman directly owns 30,826 shares of Vaxcyte common stock and holds options for 181,664 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading plan and do not necessarily indicate a change in the executive's confidence in the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the pre-planned nature of these sales mitigates this concern.

Industry Context

Insider transactions are routinely monitored and reported, providing transparency to investors. Rule 10b5-1 plans are a common mechanism for corporate insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Monitoring insider trading activity is standard practice across publicly traded companies.
• The use of Rule 10b5-1 trading plans is a common and accepted method for executives to manage their stock holdings.
• Comparable companies such as Moderna (MRNA) and BioNTech (BNTX) also see regular Form 4 filings from their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential for slight price fluctuations, but the pre-planned nature of the sales should mitigate concerns.

Key Dates